Methods and compositions for drug delivery
Compositions comprising a red blood cell (RBC) having non-toxically coupled thereto a nanoparticle having a low shear modulus or low Young's modulus of less than 10 MPa and containing a drug are provided. In one embodiment, the nanoparticles are optionally coated with protein. In another embodiment, the nanoparticle has no cell-specific targeting moiety or tissue-specific targeting moiety or organ-specific targeting moiety associated therewith. Methods of delivering selected drugs to target organs use these compositions both in vivo and ex vivo treatment of disease and for imaging.
1. A method for delivering a drug to a selected organ or tissue of a mammalian subject having a disease, the method comprising intravenously or intraarterially administering to the subject a composition comprising a red blood cell having nanoparticles physisorbed thereto, said nanoparticles having a shear modulus or Young's modulus of less than 10 MPa and containing a drug, wherein following administration of the composition said nanoparticles are transferred from the red blood cell to the vascular cells of a first capillary bed encountered downstream of the site of intravenous or intraarterial administration, said capillary bed being in the selected organ or tissue, and wherein said nanoparticles release the drug for delivery of the drug to said selected organ or tissue.
2. The method according to claim 1 , wherein the nanoparticles are characterized by having at least one of
(a) a shear modulus of less than 1 MPa;
(b) a hydrophilic exterior;
(c) a coating with a biomolecule that does not induce an immunological reaction to the composition in a mammalian subject;
(d) a globular shape with a diameter of about 10 to 1000 nm; and
(e) no cell-specific targeting moiety or tissue-specific targeting moiety or organ-specific targeting moiety associated therewith.
3. The method according to claim 2 , wherein said biomolecule is a protein or albumin or IgG.
4. The method according to claim 1 , wherein the nanoparticles are hydrogels or liposomes.
5. The method according to claim 4 , wherein said hydrogel nanoparticles are synthetic constructs of lysozyme and dextran or wherein the hydrogel nanoparticles are about 300 nm in size.
6. The method according to claim 1 , wherein the nanoparticles are miscible with endothelial glycocalyx or are characterized by release kinetics permitting greater than 50% of the drug load to be released within about 1 hour after administration in vivo.
7. The method according to claim 1 , wherein said drug is a water miscible compound.
8. The method according to claim 1 , wherein said nanoparticles are hydrogels containing a water-miscible drug selected from one or more of albuterol, dexamethasone, and palifermin.
9. The method according to claim 8 , wherein the nanoparticles are lysozyme-dextran hydrogels, optionally coated with albumin or IgG.
10. The method according to claim 1 , wherein said drug is released from the nanoparticles within 60 minutes of administration.
11. The method according to claim 1 , wherein the selected target organ is the lungs.
12. The method according to claim 1 , wherein
(a) the disease is ARDS, pneumonia, interstitial lung disease, idiopathic pulmonary fibrosis, post-pulmonary embolism; pulmonary capilliaritis syndrome, or emphysema; or
(b) said disease is ARDS and wherein said drug is one of more of albuterol, dexamethasone, and palifermin.
13. The method according to claim 1 , further comprising rotating or agitating said composition before administering to prevent settling and aggregation of red blood cells.
14. The method according to claim 1 , wherein said drug is a therapeutic drug, a prophylactic drug, an imaging or diagnostic drug, an anti-rejection drug, an anti-inflammatory agent, a pro-angiogenic factor, an anti-edema agent, or an agent that prevents ischemia-reperfusion injury.
15. A method for delivering a drug to a selected organ or tissue of a mammalian subject, the method comprising administering via intra-arterial catheter to the subject a composition comprising a red blood cell having nanoparticles physisorbed thereto, said nanoparticles having a shear modulus or Young's modulus of less than 10 MPa and containing a drug, wherein following administration of the composition said nanoparticles are transferred from the red blood cell to the vascular cells of a first capillary bed encountered downstream of the intra-arterial catheter, said first capillary bed being in the selected organ or tissue, and wherein said nanoparticles release the drug for delivery of the drug to said selected organ or tissue.
16. The method according to claim 15 , wherein said drug is a water miscible compound.
17. The method according to claim 15 , wherein said nanoparticle is a hydrogel containing a water-miscible drug selected from one or more of albuterol, dexamethasone and palifermin.
18. The method according to claim 15 , wherein the selected organ is the brain or heart.
19. A method for delivering a drug to a selected organ designated for transplantation, the method comprising administering to the organ ex vivo, via intraarterial or intravenous injection, a composition comprising a red blood cell having nanoparticles physisorbed thereto, said nanoparticles having a shear modulus or Young's modulus of less than 10 MPa and containing a drug, wherein following administration of the composition said nanoparticles are transferred from the red blood cell to the vascular cells of a first capillary bed encountered downstream of the site of administration, and wherein said nanoparticles release the drug for delivery of the drug to the selected organ.